Dova Pharmaceuticals (DOVA) Set to Announce Quarterly Earnings on Tuesday

Dova Pharmaceuticals (NASDAQ:DOVA) will be announcing its earnings results before the market opens on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.57) per share for the quarter.

Dova Pharmaceuticals (NASDAQ:DOVA) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.10. The firm had revenue of $4.00 million for the quarter, compared to the consensus estimate of $3.46 million. Dova Pharmaceuticals had a negative net margin of 521.67% and a negative return on equity of 87.20%. On average, analysts expect Dova Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:DOVA opened at $16.00 on Monday. The company has a market capitalization of $455.68 million, a PE ratio of -6.15 and a beta of 2.57. The firm has a fifty day moving average of $14.20. Dova Pharmaceuticals has a twelve month low of $5.62 and a twelve month high of $26.49. The company has a current ratio of 4.46, a quick ratio of 4.27 and a debt-to-equity ratio of 0.20.

Several analysts recently weighed in on the stock. HC Wainwright lifted their price target on shares of Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, June 27th. JPMorgan Chase & Co. lifted their price target on shares of Dova Pharmaceuticals from $13.00 to $15.00 and gave the company an “underweight” rating in a report on Friday, July 12th. Evercore ISI upgraded shares of Dova Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $15.00 price target on the stock in a report on Monday, July 1st. BidaskClub upgraded shares of Dova Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday. Finally, Zacks Investment Research cut shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 16th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Dova Pharmaceuticals presently has an average rating of “Buy” and an average target price of $27.13.

In other news, CEO David Zaccardelli sold 10,450 shares of Dova Pharmaceuticals stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $15.94, for a total value of $166,573.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jason Hoitt sold 7,580 shares of Dova Pharmaceuticals stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $15.26, for a total value of $115,670.80. The disclosure for this sale can be found here. In the last ninety days, insiders bought 582,854 shares of company stock valued at $8,243,825 and sold 27,807 shares valued at $422,464. 60.30% of the stock is owned by insiders.

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Further Reading: How Does the Quiet Period Work?

Earnings History for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.